Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GW Pharmaceuticals PLC

www.gwpharm.com

Latest From GW Pharmaceuticals PLC

Bayer's Vitrakvi On Track To Become EU’s First Tumor-Agnostic Cancer Treatment

Five new medicines, including what could become Europe’s first ever tumor-agnostic cancer treatment, have been recommended for approval by the European Medicines Agency.
Europe Approvals

GW Pharma’s Cannabidiol For Seizures One Step Closer To European Approval

The CHMP has issued a positive opinion for Epidyolex for two rare conditions. The cannabidiol product was approved in the US in 2018.

Approvals Neurology

Drug Innovation Needs Exclusivity For Some Natural Substances, PhRMA Recommends

In comments on VMS industry oversight, PhRMA recommends FDA adhere to clear regulations that determine whether substances are eligible for use as dietary ingredients. DSHEA makes clear that some dietary ingredients are not eligible for use VMS products.
Dietary Supplements Regulation

With Another Warning, FDA Pledges Report On CBD Use In Non-drug Products

CBD claim warning comes as FDA reviews more than 4,200 comments on its initiative to determine whether to open regulatory paths for firms to market non-drug products containing hemp- or cannabis-derived ingredients. From Deputy Commissioner Abernethy statement included in announcement about warning, it appears agency is getting message industry trade groups stated in comments that enforcement over non-drug products containing CBD cannot wait.
Dietary Supplements Regulation
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • GW Pharmaceuticals PLC
  • Senior Management
  • Justin Gover, CEO
    Scott Giacobello, CFO
    Chris Tovey, COO
    Volker Knappertz , MD, CMO
  • Contact Info
  • GW Pharmaceuticals PLC
    Phone: (44) 1223 266800
    Sovereign House
    Vision Park
    Histon, Cambridge, CB24 9BZ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register